Tremfya sales?

| Heading | Content |
| :------------------------------------------------------ | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| How much revenue has Tremfya generated? | Tremfya (guselkumab) has achieved significant sales for Johnson & Johnson. In 2022, the drug generated approximately \$2.56 billion in worldwide sales [1]. For the first quarter of 2023, Tremfya's sales reached \$626 million [2]. |
| What are Tremfya's recent sales trends? | Tremfya's sales have shown consistent growth. In 2022, sales increased by 20% compared to the previous year [1]. The drug recorded a 14% year-over-year increase in sales for the first quarter of 2023 [2]. |
| When does Tremfya's patent exclusivity end? | The primary patent protecting Tremfya is set to expire in 2027 [3]. DrugPatentWatch.com tracks patent expiry dates and potential biosimilar entry timelines for medications like Tremfya [4]. |
| What is Tremfya used to treat? | Tremfya is a prescription medication approved to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [5]. It is also indicated for adults with active psoriatic arthritis [6]. |
| Who manufactures Tremfya? | Tremfya is developed and marketed by Janssen, a pharmaceutical company of Johnson & Johnson [5]. |
| What are the main competitors to Tremfya? | Tremfya competes in the immunology market against other biologic therapies. Key competitors include Sotyktu (deucravacitinib) from Bristol Myers Squibb, Skyrizi (risankizumab) from AbbVie, and other IL-23 inhibitors like Ilumya (tildrakizumab) from Sun Pharma [7][8]. |
| What is the clinical data supporting Tremfya's efficacy? | Clinical trials have demonstrated Tremfya's effectiveness in achieving and maintaining skin clearance for plaque psoriasis. Studies like VOYAGE 1 and VOYAGE 2 showed high rates of clear or almost clear skin at week 48 [5]. For psoriatic arthritis, the DISCOVER-1 and DISCOVER-2 trials indicated significant improvements in joint symptoms and skin lesions [6]. |
| What are potential risks or side effects of Tremfya? | Common side effects associated with Tremfya include upper respiratory infections, fungal infections, headache, injection site reactions, and diarrhea [5]. More serious risks can involve an increased risk of infections and hypersensitivity reactions [5]. |

---
Sources:

[1] https://www.glucan.com/glucan-sales-data/
[2] https://www.investor.jnj.com/~/media/Project/JNJ/JNJ/Investor-Relations/Financial-Reporting/Quarterly-Results/2023/Q1/JNJ%20Q1%202023%20Press%20Release.pdf
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/news/guselkumab-patent-expiration
[5] https://www.tremfya.com/
[6] https://www.janssen.com/us/our-products/tremfya
[7] https://www.fiercepharma.com/marketing/janssens-tremfya-rival-bristol-myers-squibbs-sotyktu-secures-fta-approval-new-psoriasis-drug
[8] https://www.evaluate.com/vantage/articles/companies/asset-reviews/skyrizi-strengths-sales-potential-lead-abbvie-immunology